Compare Five9 Inc (FIVN) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five9 Inc vs GeneDx Holdings Corp — how do they compare? Five9 Inc trades at $25.12 (market cap $1.90B), while GeneDx Holdings Corp trades at $62.73 (market cap $1.96B). The key difference: Five9 Inc and GeneDx Holdings Corp are close in size by market cap, and Five9 Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| FIVN | WGS | |
|---|---|---|
Market Cap | $1.90B | $1.96B |
Sector | Technology | Technology |
52-Week High | $29.16 | $167.51 |
52-Week Low | $13.61 | $34.51 |
Enterprise Value | $1.98B | $1.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) trades at $25.05, down 2.07% on the day, with a bullish technical outlook supported by moving averages. The company shows improving fundamentals, with revenue growing from $779M in 2022 to $1.15B in 2025 and turning profitable with net income of $39.42M. Recent news highlights AI product launches and workplace awards, while legal scrutiny on insider conduct persists.
The stock presents a positive outlook with strong analyst support (61% buy ratings) and a consensus price target of $27.00, offering ~8% upside. Key risks include negative net cash flow, high debt levels, and ongoing legal investigations into insider fiduciary duties that could pressure sentiment.
GeneDx Holdings Corp. (WGS) trades at $65.785, up 5.37% today, but faces a bearish technical signal with the stock near resistance at $65. The company shows mixed fundamentals with strong revenue growth to $427.54M in 2025 but a net loss of -$21.02M, while analyst consensus remains bullish with a $75.40 price target. Recent news highlights multiple class-action lawsuits alleging securities fraud tied to a 49% stock decline and acquisition underperformance, creating significant investor uncertainty.
The outlook is highly conflicted: strong analyst buy ratings and recent earnings beats contrast with deepening losses, negative cash flow projections for 2026, and legal overhangs. Key risks include litigation outcomes, profitability challenges, and execution missteps, but the stock offers potential upside if the company can stabilize margins and resolve legal issues amid high institutional skepticism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
